Investor Presentaiton
Company overview
Financial review
2022 priorities
Appendix
References
CosentyxⓇ double digit demand-driven growth in Q2
Sales evolution
USD m, % cc
Ex-US
US
1,175
+12%
1,275
539
460
715
736
Q2 2021
Q2 2022
1
GROWTH
Cosentyx E
AZ
K
KL
Maintaining double-digit growth outlook for FY2022
Steady volume growth across US, EU and China
Confidence in clinical profile; >700k patients across 5 indications
GRAPPA PSA guidelines highlight Cosentyx unique benefit in axial
manifestations and proven efficacy of IL17 across all 6 domains¹
Confident in USD 7bn+ peak sales
Continued demand-led growth WW
Life cycle management - Q2 progress:
- JPSA/ ERA pediatric approvals in EU
- HS submitted in EU, US anticipated H2
- axSpA IV study (INVIGORATE 2) positive readout
- PSA IV US submission anticipated H2
WW Worldwide HS - Hidradenitis Suppurativa JPSA - Juvenile Psoriatic Arthritis ERA - Enthesitis related arthritis PSA - Psoriatic Arthritis axSpA - axial Spondyloarthritis
Assessment of Psoriasis and Psoriatic Arthritis 1. Coates et al. Nat Rev Rheumatol (2022)
IV Intra venous GRAPPA - Group for Research and
8 Investor Relations | Q2 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation